SCHEMBL10192141

SCHEMBL10192141

Cc1ccc(N(C)S(=O)(=O)C(C)C)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
MCOLN3 Q8TDD5 1/20 0.57
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
ALDH1A1 P00352 3/20 0.44
TSHR P16473 1/20 0.44
LMNA P02545 3/20 0.44
C5AR1 P21730 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
AGER Q15109 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MAPK1 P28482 1/20 0.40
GFER P55789 1/20 0.40
MCL1 Q07820 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MEN1 O00255 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6301489 0.82 NPC1 (0.45) MAPTMCOLN3CA12CA9ALDH1A1
SCHEMBL12251459 0.81 CA12 (0.48) MAPTMCOLN3CA12CA9ALDH1A1
SCHEMBL11172279 0.78 MMP2 (0.42) MAPTMCOLN3CA12CA9ALDH1A1
SCHEMBL21104531 0.77 KMT2A (0.46) MAPTCA12CA9ALDH1A1TSHR
SCHEMBL3467608 0.76 MAPT (0.63) MAPTMCOLN3CA12CA9ALDH1A1
SCHEMBL10285578 0.74 MAPT (0.61) MAPTMCOLN3CA12CA9ALDH1A1
SCHEMBL6203263 0.74 MAPT (0.61) MAPTMCOLN3CA12CA9ALDH1A1
SCHEMBL10192055 0.72 MAPT (0.59) MAPTMCOLN3CA12CA9ALDH1A1
SCHEMBL2008337 0.72 MAPT (1.00) MAPTMCOLN3CA12CA9ALDH1A1
SCHEMBL14212101 0.71 MAPT (0.57) MAPTMCOLN3CA12CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 US disclosed
US-7973069-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-07-05 US disclosed
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C OAT, HAVCR2, HCCS MAPT 4416/4885MCOLN3 2724/4885CA12 1807/4885
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS MAPT 4477/4885MCOLN3 3971/4885CA12 875/4885
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS MAPT 4477/4885MCOLN3 3971/4885CA12 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.